Since taking office, President Donald Trump has brusquely removed a number of top officials from their positions, including a ...

Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

Moderna surpassed Wall Street sales predictions due to strong Spring COVID booster demand but lowered its 2025 sales forecast, causing a premarket share decline. Despite a 41% revenue drop to $142 ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...

The Moderna layoffs are aimed at cutting costs amid declining vaccine sales and a shifting regulatory landscape.

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

The target is to reduce its workforce to less than 5,000 from a level of 5,800 at the end of 2024, said chief executive ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

The company last reported total revenues of $108M in Q1, down 35.3% Y/Y due to lower net product sales, particularly its ...

Moderna said it would trim roughly 10 per cent of its global workforce and have fewer than 5,000 employees by the end of the ...